APA

Parmar S., Rundhaugen L. M., Boehlke L., Riley M., Nabhan C., Raji A., Frater J. L. & Tallman M. S. (20040914). Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. : Leukemia research.

Chicago

Parmar Simrit, Rundhaugen Lynn M, Boehlke Larry, Riley MaryBeth, Nabhan Chadi, Raji Adekunle, Frater John L and Tallman Martin S. 20040914. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. : Leukemia research.

Harvard

Parmar S., Rundhaugen L. M., Boehlke L., Riley M., Nabhan C., Raji A., Frater J. L. and Tallman M. S. (20040914). Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. : Leukemia research.

MLA

Parmar Simrit, Rundhaugen Lynn M, Boehlke Larry, Riley MaryBeth, Nabhan Chadi, Raji Adekunle, Frater John L and Tallman Martin S. Phase II trial of arsenic trioxide in relapsed and refractory acute myeloid leukemia, secondary leukemia and/or newly diagnosed patients at least 65 years old. : Leukemia research. 20040914.